Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | RAF1 | P04049 | 5/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3117182 | 0.87 | SLC6A4 (0.46) | EPHX2SLC6A4SLC6A2SLC6A3RAF1 | |
| SCHEMBL2583028 | 0.84 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3FFAR4P2RX7 | |
| SCHEMBL2581539 | 0.83 | FPR2 (0.43) | SLC6A4SLC6A2SLC6A3FFAR4P2RX7 | |
| SCHEMBL2578242 | 0.82 | SLC6A2 (0.44) | SLC6A4SLC6A2SLC6A3FFAR4P2RX7 | |
| Trifluoroacetic Acid SCHEMBL2577921 | 0.81 | FFAR4 (0.49) | SLC6A4SLC6A2SLC6A3FFAR4P2RX7 | |
| SCHEMBL2582249 | 0.81 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3FFAR4P2RX7 | |
| SCHEMBL2585974 | 0.77 | SLC6A4 (0.49) | EPHX2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31071550 | 0.76 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3P2RX7 | |
| SCHEMBL12175681 | 0.76 | SLC6A4 (0.46) | SLC6A4SLC6A2SLC6A3P2RX7 | |
| SCHEMBL3118849 | 0.76 | EPHX2 (0.44) | EPHX2SLC6A4SLC6A2SLC6A3RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8049012-B2 | 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | claimed |
| EP-1899303-B1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-09-15 | — | — | EP | claimed |
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | NEURO SEARCH A/S (DK) | 2009-09-10 | — | — | US | claimed |
| EP-1899303-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | claimed |
| WO-2007000465-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | claimed |
| US-8049012-B2 | 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-11-01 | — | — | US | disclosed |
| EP-1899303-B1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2010-09-15 | — | — | EP | disclosed |
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | NEURO SEARCH A/S (DK) | 2009-09-10 | — | — | US | disclosed |
| EP-1899303-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007000465-A1 | NOVEL 3-AZA-SPIRO[5.5]UNDECANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227613-A1 | Novel 3-Aza-Spiro[5.5]Undecane Derivatives and Their Use As Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC6A3 | EPHX2 1264/4885SLC6A4 5/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.